NCT00938314终止2 期
A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 96
- 试验地点
- 23
- 主要终点
- National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90
研究概览
简要总结
The purpose of this study is:
- To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.
- To assess the safety and tolerability of NTx®-265 when given to acute ischemic stroke patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-85
- •NIHSS score 8-20
- •Stroke is ischemic in origin, supratentorial, and radiologically confirmed
- •Patient is 24-48 hours from time of stroke onset when the first dose of NTx®-265 therapy is administered
- •Reasonable expectation of availability to receive the full 9 day NTx®- 265 therapy and subsequent follow-up visits
- •Reasonable expectation that patient will receive standard post-stroke physical, occupational, speech, and cognitive therapy as indicated
- •Female patient is either not of childbearing potential or agrees to use two of the effective separate non-hormonal forms of contraception throughout the study
排除标准
- •Patients presenting with lacunar, hemorrhagic and/or brain stem stroke
- •Patients who have received tissue plasminogen activator (tPA)following the index stroke
- •Patients classified as comatose
- •Women who have tested positive for pregnancy, or are breast-feeding, or are not using a birth control
- •Serum hemoglobin > 16 grams(g)/deciliter (dL)(males) or > 14 g/dL (females); or platelet count > 400,000/cubic millimeters(mm3)
- •Advanced liver, kidney, cardiac, or pulmonary disease
- •Elevated serum bilirubin,alkaline phosphatase, aspartate aminotransferase (AST) or alanine transaminase (ALT),creatinine, or prostate-specific antigen (PSA) levels
- •Patients with a known history of hypercoagulability
- •Expected survival < 1 year
- •Allergy or other contraindication to hCG or EPO
- •A known diagnosis of cancer in the previous 5 years
- •Uncontrolled hypertension
- •Use of either hCG or epoetin alfa within the previous 90 days
- •Any condition known to elevate hCG
- •Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS)≥ 2
- •Any patients not living independently
- •Any other medical condition or degree of stroke such that, in the investigator's opinion, the patient should not be included in the trial
- •With the exception of the qualifying stroke, any other stroke within the previous 3 months
- •Patients who cannot take anti-platelet or anti-coagulant therapy
- •Pre-existing and active major psychiatric or other chronic neurological disease
- •Alcohol abuse or have a history of substance abuse or dependency within 12 months prior to the study
- •Currently participating in another investigational study
研究组 & 干预措施
NTx®-265 Low Dose
Experimental
hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
干预措施: human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (Drug)
NTx®-265 Medium Dose
Experimental
hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
干预措施: human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (Drug)
NTx®-265 High Dose
Experimental
hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
干预措施: human chorionic gonadotropin (hCG), then epoetin alfa (EPO) (Drug)
Saline Placebo
Placebo Comparator
干预措施: Saline Placebo (Drug)
结局指标
主要结局
National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90
时间窗: Baseline and Day 90
The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Values range from 0 (no deficit) to 42 (dead).
次要结局
- NIHSS Response >=4 at Day 90(Baseline and Day 90)
- NIHSS Change From Baseline at Day 30(Baseline and Day 30)
- Modified Rankin Scale (mRS) Response <=2 at Day 90(Day 90)
- Barthel Index at Day 90(Day 90)
- Action Research Arm Test (ARAT) Change From Baseline at Day 90(Baseline and Day 90)
- Gait Velocity Test Change From Baseline at Day 90(Baseline and Day 90)
- Boston Naming Test (BNT) Change From Baseline at Day 90(Baseline and Day 90)
- Line Cancellation Test Change From Baseline at Day 90(Baseline and Day 90)
- Trails A Test Change From Baseline at Day 90(Baseline and Day 90)
- Trails B Test Change From Baseline at Day 90(Baseline and Day 90)
- Geriatric Depression Scale at Day 90(Day 90)
研究者
研究点 (23)
Loading locations...
相似试验
终止
2 期
REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke PatientsStrokeNCT00663416Stem Cell Therapeutics Corp.134
已完成
2 期
Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2JaundiceStrokeRhabdomyolysisNCT01976936Columbia University162
已完成
2 期
Study of NeuroAid In Enhancing Recovery After StrokeStrokeCerebral InfarctionNCT00721825Moleac Pte Ltd.40
已完成
2 期
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)Brain InfarctionStrokeNCT01977456Arthur Pancioli27
已完成
3 期
Thrombolysis of Urokinase for Minor StrokeMinor StrokeNCT04420351The First Affiliated Hospital of Zhengzhou University1,005